Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.04 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: lby-135, dulanermin, drozitumab +4 | 0.81 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 237 | 0.85 |
| pathways Reactome | 8 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 5633
Sealed predictions
- TNFRSF10B in dopamine neurons, braak+0.21 (p 0.591) → -0.23 (p 0.549)receipt 5639
Swarm cases
receipt 5639: TNFRSF10B in dopamine neurons, braak
- power
- full sample -0.07 (p 0.787, n 18), 95% CI -0.52 to +0.41. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.08 (p 0.767, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.14 (p 0.567, n 18). could be the mix.
- skeptic
- leave-one-out range -0.16 to +0.05, sign flips 2; without severely affected donors -0.07 (p 0.787, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TNFRSF10B in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts